TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

AMRING PHARMS

NeurologyCardiovascularInfectious Disease
Pharma

AMRING PHARMS is a pharmaceutical company focused on Neurology, Cardiovascular, Infectious Disease. Key products include NEOSTIGMINE METHYLSULFATE.

2008
Since
11
Drugs
-
Trials
113
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

ARSENIC TRIOXIDE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LATANOPROST 2026-01-30
Labeling
LATANOPROST 2026-01-30
Labeling
LATANOPROST 2026-01-30
Labeling
LAMOTRIGINE 2026-01-08
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 33%
2 drugs
Cardiovascular 17%
1 drugs
Infectious Disease 17%
1 drugs
Dermatology 17%
1 drugs
Immunology 17%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

PAI HOLDINGS PHARM big-pharma
Dermatology, Infectious Disease, Neurology, Cardiovascular, Immunology
Pfizer big-pharma
Infectious Disease, Dermatology, Immunology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Immunology
BAUSCH AND LOMB specialty
Cardiovascular, Infectious Disease, Dermatology, Immunology
Merck big-pharma
Infectious Disease, Cardiovascular, Immunology